Salmeterol Xinafoate
Salmeterol Xinafoate structure
|
Common Name | Salmeterol Xinafoate | ||
|---|---|---|---|---|
| CAS Number | 94749-08-3 | Molecular Weight | 603.745 | |
| Density | 1.112g/cm3 | Boiling Point | 603ºC at 760 mmHg | |
| Molecular Formula | C36H45NO7 | Melting Point | 137-138ºC | |
| MSDS | Chinese USA | Flash Point | 318.5ºC | |
|
Safety of bronchial thermoplasty in patients with severe refractory asthma.
Ann. Allergy Asthma Immunol. 111(5) , 402-7, (2013) Patients with severe refractory asthma treated with bronchial thermoplasty (BT), a bronchoscopic procedure that improves asthma control by reducing excess airway smooth muscle, were followed up for 5 years to evaluate long-term safety of this procedure.To ass... |
|
|
Early intervention with high-dose inhaled corticosteroids for control of acute asthma exacerbations at home and improved outcomes: a randomized controlled trial.
Allergy Asthma Proc. 33(6) , 508-13, (2012) Various studies have examined the efficacy of a temporary increase in the dose of inhaled corticosteroids (ICSs) during acute asthma exacerbations with conflicting results. This study was designed to investigate the efficacy of high-dose ICSs in controlling a... |
|
|
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.
Cochrane Database Syst. Rev. 3 , CD006922, (2013) Epidemiological evidence has suggested a link between beta2-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta2-agonists are safe. This is an updat... |
|
|
Influence of β(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol.
Ann. Allergy Asthma Immunol. 110(3) , 156-60, (2013) New evidence suggests that different β(2)-adrenergic receptor (β2AR) polymorphisms may influence asthma control in patients receiving long-acting β(2)agonists (LABAs) as regular therapy.To determine the influence of β2AR polymorphisms on asthma exacerbations ... |
|
|
An evaluation of asthma medication utilization for risk evaluation and mitigation strategies (REMS) in the United States: 2005-2011.
J. Asthma 50(7) , 776-82, (2013) The purpose of this study was to assess drug utilization patterns of fluticasone propionate (FP)/salmeterol (SAL) combination (FSC) and SAL over the 7-year period of 2005-2011 in patients with asthma as part of the Risk Evaluation and Mitigation Strategies (R... |
|
|
Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting β2 agonist: observational matched cohort study (PATHOS).
BMJ 346 , f3306, (2013) To investigate the occurrence of pneumonia and pneumonia related events in patients with chronic obstructive pulmonary disease (COPD) treated with two different fixed combinations of inhaled corticosteroid/long acting β2 agonist.Observational retrospective pa... |
|
|
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.
Int. J. Chron. Obstruct. Pulmon. Dis. 8 , 53-64, (2013) Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are ind... |
|
|
Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide.
Am. J. Respir. Crit. Care Med. 188(12) , 1407-12, (2013) β2-Agonists are the treatment of choice for exercise-induced bronchoconstriction (EIB) and act through specific receptors (ADRB2). Arg16Gly polymorphisms have been shown to affect responses to regular use of β2-agonists.To evaluate the influence of the Arg16G... |
|
|
Ten years of tiotropium: clinical impact and patient perspectives.
Int. J. Chron. Obstruct. Pulmon. Dis. 8 , 117-25, (2013) Tiotropium bromide is an anticholinergic agent that has gained worldwide acceptance as a first-line, once daily maintenance therapy for patients with moderate-to-severe chronic obstructive pulmonary disease. The purpose of this review is to synthesize the evi... |
|
|
Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety.
Health Technol. Assess. 17(4) , 1-218, (2013) Asthma affects one in eight children in the UK. National management guidelines have been available for many years but, unlike in adults, studies in children have been few, with their methodologies often based on inappropriate adult models. Sound medical evide... |